Skip to main content

Table 3 Expected and infused prothombin complex concentrate dose according to initial international normalized ratio

From: Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice

Initial INR 2-2.5
(n= 57)
2.5-3
(n= 53)
3-3.5
(n= 49)
> 3.5
(n= 249)
Unavailable
(n= 71)
Expected PCC dose, IU/kg      
   Mean 10 20 25 > 30 25
   Range 7.5-15 15-22.5 22.5-30   
Infused PCC dose, IU/kg      
   Mean ± SD 24.9 ± 9.6 22.5 ± 6.9 27.1 ± 9.3 26.2 ± 10.2 25.2 ± 9.4
Target INR achievementa 40 (81.6) 37 (84.1) 30 (79.0) 171 (79.9) 46 (74.2)
Bleeding controlleda 38 (74.5) 34 (80.0) 27 (81.8) 175 (82.2) 50 (76.9)
  1. Results are expressed as number (percentage) or as mean ± standard deviation (SD). The results are presented in patients with documented prothombin complex concentrate (PCC) dose and initial international normalized ratio (INR) of at least 2 or unavailable INR (n = 479). aPercentages are calculated on the number of patients with a documented response.